Novartis anti-inflammatory drug Ilaris is approved by the US FDA: the first drug to treat adult Still’s disease (AOSD)!

The U.S. Food and Drug Administration (FDA) recently approved Novartis' anti-inflammatory drug Ilaris (Elater, generic name: canakimumab, kanazumab) for the treatment of active Still's disease, including Adult paroxysmal Still's disease (AOSD). Previously, Ilaris has been granted priority review designation (PRD) for the treatment of Still's disease. It is worth mentioning

Read More
Share :